肝癌射频消融术后联合替吉奥节拍化疗的疗效评价

目的 探讨肝癌患者射频消融术后口服低剂量替吉奥的节拍化疗临床疗效。方法 选择接受射频消融术的肝癌患者,按照术后是否口服替吉奥进行节拍化疗分为RFA+替吉奥组和RFA对照组,回顾性分析两组患者术后18个月内的临床疗效,评价其原发肿瘤控制率和无疾病进展时间。结果 随访观察显示,术后9个月RFA+替吉奥组的肿瘤控制率为93.3%,RFA对照组肿瘤控制率为73.4%,差异有统计学意义(P=0.038);随访18个月内,RFA+替吉奥组无疾病进展时间中位数为16.25个月,RFA对照组无疾病进展时间中位数降低为12.25个月(P＜0.001);1年无疾病进展率在RFA对照组为53.3%,显著低于RFA+替吉奥组83.3%(P=0.012)。两组均无治疗相关性死亡,主要并发症发生率为13.3%。结论 射频消融术后进行替吉奥节拍化疗治疗肝癌可以减缓肿瘤进展,延长肝癌患者的无疾病进展时间。

The therapeutic evaluation of radiofrequency ablation combined with S-1 capsules metronomic chemo-therapy for hepatocellular carcinoma

Objective To explore the clinical efficiency and safety of radiofrequency ablation combined with Tegafur,Gimeracil and Oteracil Porassium Capsules( S-1 capsules) for hepatocellular carcinoma.Methods Sixty HCC patients included in this study were underwent initial radiofrequency ablation and then they were di-vided into RFA+S-1 group and RFA control group according to the metronomic chemotherapy either with S-1 or not.The local tumor control and disease free survival outcome between the two groups were compared.Results Follow-up observation showed that the total control rate after 9 months′treatment was 93.3%in RFA+S-1 group vs.73.4%in RFA control group(P=0.038).During the 18 months of follow up,the median time for dis-ease free survival was 16.25 months in RFA+S-1 group vs.12.25 months in RFA control group( P<0.001) . One-year progression free survival rate in RFA group was 53.3%,which was significantly lower than the RFA+S-1 group(83.3%)(P=0.012).The major complication rate was 13.3%.No procedu rerelated death or severe complications occurred.Conclusion Metronomic chemotherapy with S-1 following initial radiofrequency ablation delays tumor progression and prolongs overall survival of patients with HCC tumors.